Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Double-dummy, Active Controlled Study of Canakinumab (ACZ885) on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/ or Colchicine Are Contraindicated, Not Tolerated or Ineffective.

Trial Profile

A Randomized, Double-blind, Double-dummy, Active Controlled Study of Canakinumab (ACZ885) on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/ or Colchicine Are Contraindicated, Not Tolerated or Ineffective.

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Canakinumab (Primary) ; Triamcinolone
  • Indications Gouty arthritis
  • Focus Biomarker; Registrational; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 07 Jun 2017 Status changed from completed to discontinued.
    • 14 Oct 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 23 Feb 2015 Planned End Date changed from 1 Jul 2015 to 1 Aug 2015 as reported by ClinicalTrials.gov record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top